We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
-10.74%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$582M
AUM Growth
-$123M
Cap. Flow
+$8.6M
Cap. Flow %
1.48%
Top 10 Hldgs %
47.58%
Holding
53
New
6
Increased
26
Reduced
8
Closed
10

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$33M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$15.8M
3
JANX icon
Janux Therapeutics
JANX
+$12.7M
4
UTHR icon
United Therapeutics
UTHR
+$12.3M
5
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.2M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$26.9M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$24.4M
3
IRON icon
Disc Medicine
IRON
+$22M
4
SRRK icon
Scholar Rock
SRRK
+$18M
5
AKRO
Akero Therapeutics
AKRO
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
26
Xenon Pharmaceuticals
XENE
$5.81B
$10.2M 1.75%
303,398
+106,186
+54% +$4.03M
VERA icon
27
Vera Therapeutics
VERA
$2.46B
$9.99M 1.72%
415,719
+157,931
+61% +$5.07M
REPL icon
28
Replimune Group
REPL
$1.46B
$9.62M 1.65%
987,036
+37,036
+4% +$458K
IOVA icon
29
Iovance Biotherapeutics
IOVA
$3.63B
$9.02M 1.55%
2,708,582
+34,677
+1% +$179K
CNTX icon
30
Context Therapeutics
CNTX
$35.3M
$9M 1.55%
14,705,882
– –
MBX
31
MBX Biosciences
MBX
$3.03B
$8.36M 1.44%
+1,132,950
New +$12M
NUVB icon
32
Nuvation Bio
NUVB
$2.34B
$8.19M 1.41%
4,652,243
+488,065
+12% +$1.11M
ORIC icon
33
Oric Pharmaceuticals
ORIC
$1.37B
$7.81M 1.34%
+1,399,514
New +$12.2M
IDYA icon
34
IDEAYA Biosciences
IDYA
$3.87B
$7.05M 1.21%
430,161
+16,126
+4% +$344K
SLDB icon
35
Solid Biosciences
SLDB
$1.05B
$6.08M 1.04%
+1,642,356
New +$7.03M
RLAY icon
36
Relay Therapeutics
RLAY
$4.11B
$6.02M 1.03%
2,295,924
+27,099
+1% +$106K
STOK icon
37
Stoke Therapeutics
STOK
$2.04B
$4.62M 0.79%
693,988
+8,162
+1% +$76.1K
VERU icon
38
Veru
VERU
$44.8M
$3.23M 0.56%
659,273
+230,736
+54% +$1.43M
HOWL icon
39
Werewolf Therapeutics
HOWL
$45.8M
$2.34M 0.4%
2,408,810
+20,799
+0.9% +$27.2K
DSGN icon
40
Design Therapeutics
DSGN
$946M
$2.17M 0.37%
562,943
+3,396
+0.6% +$16.2K
ADAP
41
DELISTED
Adaptimmune Therapeutics
ADAP
$964K 0.17%
4,894,344
-201,568
-4% -$104K
RPTX
42
DELISTED
Repare Therapeutics
RPTX
$808K 0.14%
819,924
-411,230
-33% -$496K
ALXO icon
43
ALX Oncology
ALXO
$277M
$343K 0.06%
550,000
-841,434
-60% -$1.01M
AKRO
44
DELISTED
Akero Therapeutics
AKRO
– –
-460,617
Closed -$12.8M
AQST icon
45
Aquestive Therapeutics
AQST
$630M
– –
-1,611,833
Closed -$5.74M
ARCT icon
46
Arcturus Therapeutics
ARCT
$432M
– –
-459,943
Closed -$7.81M
AXSM icon
47
Axsome Therapeutics
AXSM
$10.4B
– –
-50,000
Closed -$4.23M
INSM icon
48
Insmed
INSM
$25.9B
– –
-389,611
Closed -$26.9M
IRON icon
49
Disc Medicine
IRON
$3.07B
– –
-346,401
Closed -$22M
MIRM icon
50
Mirum Pharmaceuticals
MIRM
$5.94B
– –
-589,579
Closed -$24.4M
1
2
3

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q1 2025 Portfolio in Review

As of Q1 2025, MPM BioImpact held 53 positions worth $582M, down 17% from $704M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

MPM BioImpact's Q1 2025 filing shows 6 new, 26 increased, 8 reduced and 10 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 100,415 shares worth $33.3M. The largest sale was Insmed, an estimated $26.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • MPM BioImpact's largest Q1 2025 buy was Madrigal Pharmaceuticals: 100,415 shares worth $33.3M.
  • MPM BioImpact added most to Janux Therapeutics in Q1 2025, an estimated $12.7M increase.
  • MPM BioImpact's biggest Q1 2025 reduction was ALX Oncology, cutting an estimated $1.01M.
  • MPM BioImpact fully exited Insmed in Q1 2025, selling an estimated $26.9M.
  • MPM BioImpact's ten largest holdings make up 48% of its $582M portfolio in Q1 2025.
  • MPM BioImpact opened 6 new positions and closed 10 in Q1 2025.
  • MPM BioImpact's portfolio value fell 17% quarter-over-quarter to $582M.

Based on MPM BioImpact's 13F filing for Q1 2025, filed 15 May 2025.